51 stories across all digests
Three months into its launch, oral Wegovy has driven explosive prescription demand, largely attracting new patients who avoided injections. Early data suggest the pill is expanding the obesity market rather than cannibalizing injectable users.
Eli Lilly launched Foundayo on April 1 at $25/month for insured patients and $149 self-pay. The ATTAIN-1 trial showed 12.4% average body weight loss on the highest dose.
Noom acquired Tailor Made Compounding, a licensed 503A pharmacy in 46 states serving 400+ clinics, offering compounded peptides including sermorelin, GHK-Cu, and oxytocin.
Amazon Pharmacy expanded access to the new oral Wegovy pill with both insurance and cash-pay options, signaling a broader retail push to capitalize on surging oral GLP-1 demand.
Injectable semaglutide and tirzepatide will drop to ~$350/month initially and $245/month within two years, down from current list prices of $1,000–$1,350/month.
Wall Street bets GLP-1 drugs will transform food. Packaged-food giants are down 50%+ from peaks. Goldman projects these drugs could add over 1% to GDP if adoption reaches 60 million Americans by 2028.
Beijing-based Syneron Bio raised $150M in Series B funding with AstraZeneca among investors to develop macrocyclic peptide drugs. The FDA also proposed a new expedited IND pathway.
OrbiMed-incubated startup revealed $89M in funding to develop oral peptide drugs with biologic-level efficacy. Lead program targets asthma and is on track for clinical trials.
Industry analysis highlights CagriSema (cagrilintide + semaglutide) Phase 3 data showing 14.2% weight loss in type 2 diabetes adults, positioning it as a major Novo Nordisk pipeline asset.
Deep dive into the retatrutide hype cycle triggered by Andrew Huberman's endorsement and looksmaxxing influencers. Frames the triple-agonist as potentially more consequential than Ozempic.
CBC investigation compares the peptide trend to historical pseudoscience, with scientists emphasizing no large-scale human trials exist for peptides sold by influencers.
Analysis covers Novo's competitive positioning including ORION study results comparing oral semaglutide against orforglipron, plus up to 48% price cuts in India.
WeightWatchers began offering oral Wegovy with promotional pricing. Clinical trials showed 13.6% body weight loss with oral formulation versus 14.9% injectable.
GoodRx announced oral semaglutide availability via its telemedicine platform at $149 for lower doses, matching Novo Nordisk pricing and intensifying the GLP-1 price war.
The regulated peptide market is worth $50 billion and projected to double by the early 2030s. Unregulated peptides like BPC-157 and TB-500 lack rigorous human safety data and are increasingly sourced from gray-market Chinese distributors.
Eli Lilly's Foundayo (orforglipron) won FDA approval with aggressive pricing as low as $25/month with savings card. Medicare Part D coverage could bring costs to $50/month starting July 2026.
A physician essays about a patient who stopped her statin despite high coronary calcium yet continues injecting BPC-157 ordered online, highlighting the growing trust gap between consumer-hyped peptides and evidence-backed medications.
With one in ten American adults already on GLP-1 drugs, next-generation medications including Foundayo and retatrutide could reach the ~25% of patients who don't respond to current GLP-1 monotherapies.